Menu
Recruiting NCT04938986

Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer

No phase Interventional Non Metastatic Colorectal Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: IMMUNOSCORE®.
Who it may be relevant to
Registry conditions: Non Metastatic Colorectal Cancer. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer : Prospective Cohort Comparing the Recommandation for Patient Care According to the Immunoscore® With the Standard Care Decision.

Overview

Evaluate the patient care recommandation induced by the IMMUNOSCORE® result

Interventions

  • Diagnostic test IMMUNOSCORE®
    recommendation for patient care according to the result of the IMMUNOSCORE®

Primary outcome measures

  • Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision [Time frame: 5 years]
Secondary outcome measures (4)
  • Replication error (RER) phenotype [Time frame: 6 and 9 months]
  • KRAS, NRAS and BRAF mutations [Time frame: 6 and 9 months]
  • Ratio of ciruclating tumor DNA level [Time frame: 6 and 9 months]
  • Actual survival (patient alive without recurrence, alive with recurrence, dead) [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • age between 18 and 80 inclusive;
  • histologically confirmed colon adenocarcinoma;
  • having undergone a curative resection of stage I, II or III colorectal cancer;
  • diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2;
  • eligible to receive 6 months of adjuvant chemotherapy;
  • having given free, informed and written consent;
  • agreeing to the use of a tumor sample for research purposes;
  • being affiliated to a social security system.

Exclusion criteria

  • pregnant or breastfeeding women
  • legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study.
  • history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled
  • person subject to a safeguard measure.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

France · 2 centers
  • Hôpital Européen — Marseille
  • Hopital Saint Joseph — Marseille

Identifiers

NCT: NCT04938986 · PPC-IS

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗